Dr. Bret E. Friday, MD
Medical Oncology (Medical Oncology Physician)
400 East 3rd St
Duluth, MN 55805
Who else practices at this address →
St. Louis County includes primary care (17% of residents) and dental (35% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 247
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Emory University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MN license 54714
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Essentia Health Duluth Duluth, MN
- St Marys Hospital Superior Superior, WI
- Essentia Health Virginia Virginia, MN
- Rainy Lake Medical Center International Falls, MN
- Essentia Health Northern Pines Medical Center Aurora, MN
Medical groups
- The Duluth Clinic LTD (1,144 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 247
- Services billed
- 575
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 276 | 108 |
| Established patient office or other outpatient visit, 20-29 minutes | 148 | 105 |
| Established patient office or other outpatient visit, 40-54 minutes | 64 | 40 |
| Telephone medical discussion with physician, 11-20 minutes | 41 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Duluth, MN | 198 |
| Prednisone Other prescribers in Duluth, MN | 98 |
| Prochlorperazine Maleate Other prescribers in Duluth, MN | 91 |
| Acyclovir Other prescribers in Duluth, MN | 67 |
| Dexamethasone Other prescribers in Duluth, MN | 65 |
| Imbruvica (ibrutinib) | 61 |
| Xarelto (rivaroxaban) Other prescribers in Duluth, MN | 55 |
| Revlimid (lenalidomide) | 53 |
| Gabapentin Other prescribers in Duluth, MN | 50 |
| Potassium Chloride Other prescribers in Duluth, MN | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $30.94 in total to this clinician.
| Novocure Inc. | $30.94 |
|---|
| Food and Beverage | $30.94 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $230,390 in research payments for these studies, mostly to the institutions running them.
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06577441 - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - Pallaspalbociclib collaborative adjuvant studya randomized phase iii trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hr or HER2 early breast cancer WI…
Pfizer Inc. - Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
AstraZeneca Pharmaceuticals LP - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.